ULTRA-LOW SEVERE AGVHD AND FAVORABLE SAFETY PROFILE WITH ABATACEPT + ATG IN CNI-INTOLERANT HIGH-RISK ALLOGENEIC TRANSPLANT RECIPIENTS (EBMT 2026) - Feb 7, 2026 - Abstract #P139; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "Letermovir prophylaxis began within 6 days post-transplant. Abatacept combined with ATG yielded a low incidence of severe aGVHD with acceptable infectious and toxicity profiles in CNI-intolerant, high-risk HSCT recipients. The incidence of EBV viremia is consistent with previous reports and comparable to that in HLA-mismatched transplants. This regimen represents a feasible alternative prophylaxis strategy and warrants validation in larger prospective studies."
Clinical • Acute Graft versus Host Disease • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Respiratory Diseases • T Acute Lymphoblastic Leukemia • Transplantation
|
|
Nannan Li1; Jianping Zhang1
|